In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Medicine and Science News Releases
View recent medicine and science-related news releases.
As health advocates gear up for this year’s Great American Smokeout, childhood cancer survivors who need help with smoking cessation can receive free counseling and nicotine replacement therapy from St. Jude Children’s Research Hospital.
St. Jude Children’s Research Hospital scientists lead effort that reveals new details linking lipid build-up with catastrophic calcium imbalance in brain cells of patients with rare, inherited disorder.
St. Jude Children’s Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Arthur Nienhuis, M.D., of St. Jude Children’s Research Hospital, is the recipient of the 2009 Mentor Award from the American Society of Hematology (ASH).
St. Jude Children’s Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).
St. Jude Children’s Research Hospital has been listed among the top 10 “Best Places to Work in Academia” by The Scientist magazine—this year’s seventh place ranking is the fourth straight year the institution has placed in the top 10.
Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.
Michael Kastan, MD, PhD, and Mary Relling, PharmD, of St. Jude Children’s Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.
St. Jude Children’s Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.
Adults who survived childhood cancer return to St. Jude Children’s Research Hospital to celebrate victory over disease and mark the After Completion of Therapy (ACT) Clinic’s 25th anniversary.
September is National Childhood Cancer Awareness Month, but for researchers at St. Jude Children's Research Hospital it is a year round mission to research new ways to help more children live long, active lives while also working to better understand the challenges childhood cancer survivors face.
Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.
Mary Lynn Carver has joined St. Jude Children's Research Hospital as senior vice president of public relations. Carver comes to Memphis, Tenn. from London where she was most recently global head of group internal communications at AstraZeneca Pharmaceuticals’ world headquarters. In her new role, Carver will oversee communications strategy and the management of public relations activities for St. Jude.
At least one strain of the H5N1 avian influenza virus leaves survivors at significantly increased risk for Parkinson’s disease and possibly other neurological problems later in life, according to new research from St. Jude Children’s Research Hospital.
Switching off a key DNA repair system in the developing nervous system is linked to smaller brain size as well as problems in brain structures vital to movement, memory and emotion, according to new research led by St. Jude Children’s Research Hospital scientists.
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps, according to new findings from St. Jude Children’s Research Hospital.
Researchers have uncovered the first cases in which HIV almost certainly was transmitted from mothers or other caregivers to children through pre-chewed food.
The molecular machinery that helps brain cells migrate to their correct place in the developing brain has been identified by scientists at St. Jude Children’s Research Hospital. The finding offers new insight into the forces that drive brain organization in developing fetuses and children during their first years.
Robert Webster, PhD, is recognized by the world’s oldest scientific academy for his contributions to the field of virology.
Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).
Charles Mullighan, MD, PhD, an assistant member in the Pathology Department at St. Jude Children’s Research Hospital, has been named a 2009 Pew Scholar in the Biomedical Sciences. He is the fourth St. Jude scientist honored.
Results of collaborative study could lead to development of new diagnostic tools and a new therapeutic target in high-risk disease.
St. Jude study of the nocturnal owl monkey suggests that evolution needed only a few genetic changes to profoundly alter eye anatomy
As the world watches the developing story of the influenza A (H1N1) outbreak, St. Jude Children’s Research Hospital is working collaboratively with other research centers to help develop an effective vaccine.
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
Nurses and staff in the Intensive Care Unit (ICU) at St. Jude Children’s Research Hospital have been recognized by the American Association of Critical-Care Nurses (AACN) with the Beacon Award for Critical Care Excellence. The award recognizes the nation’s top adult critical care, pediatric critical care and progressive care units.
Cells isolated from the eye that many scientists believed were retinal stem cells are, in fact, normal adult cells, investigators at St. Jude Children's Research Hospital have found.
Michael Dyer, a faculty member at St. Jude Children's Research Hospital, has been tapped as one of the nation’s leading scientists by the Howard Hughes Medical Institute.
Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia
St. Jude scientists’ findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases.
Results of St. Jude study could shape new treatments for secondary pneumonia
Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). Although the researchers caution that further research is needed to determine how changes in the gene, called IKZF1 or IKAROS, lead to leukemia relapse, the findings are likely to provide the basis for future diagnostic tests to assess the risk of treatment failure.
